Lua, W., Gan, S., Lane, D. et al. A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2. npj Breast Cancer 1, 15012 (2015). https://doi.org/10.1038/npjbcancer.2015.12
Therapeutic efficacy resulting from combining Trastuzumab and Pertuzumab in the treatment of Her2 overexpressing breast cancer patients has been shown to increase patient survival. This is thought to arise from inhibition of receptor dimerization and the immune tagging of the cancer cells; however, the underlying molecular mechanisms have remained enigmatic. Previously, a molecular modeling study suggested that this resulted from colocalization of the two antibodies on to the extracellular domain of Her2. We report here the experimental characterization of this interaction by measuring the binding kinetics of these two whole antibodies and their F(ab)s to the extracellular domain of Her2 in solution. We found that both antibodies (the whole antibodies and the fragments) colocalized on to Her2, but did not augment the binding of each other.
This work was supported by JCO1334i00050 from the Joint Council Office, Agency for Science, Technology, and Research, Singapore.